No Data
Mitsubishi UFJ, 2Q operating profit increased by 37.3% to 1.7569 trillion yen, announced a share buyback.
Mitsubishi UFJ <8306> announced its second-quarter results for the fiscal year ending March 2025, with operating revenue increasing by 21.1% year-on-year to 6 trillion 860.2 billion 77 million yen, and ordinary profit rising by 37.3% to 1 trillion 756.9 billion 26 million yen. Additionally, the net profit forecast for the fiscal year ending March 2025 was revised upwards from 1 trillion 500 billion yen to 1 trillion 750 billion yen. This was due to strong performance in the customer division, as well as improvements in profit margins from rising yen interest rates and the sale of shareholdings. The annual dividends plan is set at 60 yen per share, in line with previous indications.
SEMITEC: Half-Year Report - 69th Term (2024/04/01 - 2025/03/31)
SEMITEC: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)
Japan Postal Service, Japan Post Bank, Mizuho, Dai-ichi Life HD (14th) (5010-9994)
Please note that the above calendar is just a schedule and is subject to change due to company circumstances.--------------------------------------- November 14 (Thursday) <5010> Nippon Seiro <5027> AnyMind G <5029> Circlace <5033> Nulab <5034> unerry <5038> eWeLL <5074> Tes HD <5101>
Solasuto etc. [Intriguing stocks based on volume changes]
Stock closing prices, previous day changes, and volumes *＜4875＞ Medicinova 318801032700 *＜6834＞ Seiko Instruments 3875475447400 *＜6197＞ Solarst 505221824400 *＜7242＞ Kayaba 5240525437300 *＜168A＞ Itami Art 9444748900 *＜6094＞ Freak HD 70635200 *＜6862＞ Minato HD 795100121800 *＜6626＞ SEMITEC 184210084500
Dentsu Group revised downwards to 107.1 billion yen in operating profit, from 135.4 billion yen on 24 December.
Dentsu Group (4324) announced a revision of its financial estimates for the fiscal year ending in December 2024, lowering its operating profit from 135.4 billion yen to 107.1 billion yen due to anticipated revenue deficits in Asia-Pacific regions such as China and Australia, resulting in impairment losses. Additionally, expenses related to the sale of its business in Russia, against the background of the Ukrainian invasion, have exceeded expectations. Plus evaluation: Skylark (3197), Medpeer (6095), Yonshan Holdings (3962).
No Data